EcoR1 Is Launching a Second SPAC

The biopharma specialist’s hedge fund had another very strong year in 2020.

Oleg Nodelman, founder of EcoR1 Capital. (Amanda Gordon/Bloomberg)

Oleg Nodelman, founder of EcoR1 Capital.

(Amanda Gordon/Bloomberg)

One of the hottest health care-related hedge funds is planning to launch its second blank-check company one month after its first one closed on a merger deal.

EcoR1 Capital, headed by one-time Institutional Investor Hedge Fund Rising Star Oleg Nodelman, on Tuesday said in a regulatory filing that it is seeking to raise at least $150 million for Panacea Acquisition Corp.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related